Incyte Corporation (INCY)
NASDAQ: INCY · IEX Real-Time Price · USD
59.02
-1.85 (-3.04%)
At close: Jul 2, 2024, 4:00 PM
59.05
+0.03 (0.05%)
After-hours: Jul 2, 2024, 7:46 PM EDT
Incyte Employees
Incyte had 2,524 employees as of December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,492,815
Profits / Employee
$295,342
Market Cap
13.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tenet Healthcare | 106,500 |
Quest Diagnostics | 48,000 |
Dr. Reddy's Laboratories | 25,863 |
Revvity | 11,500 |
Medpace Holdings | 5,900 |
Natera | 3,293 |
Insulet | 3,000 |
Neurocrine Biosciences | 1,400 |
INCY News
- 11 hours ago - This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
- 19 days ago - Incyte Announces Final Results of Tender Offer - Business Wire
- 21 days ago - Incyte Announces Preliminary Results of Tender Offer - Business Wire
- 25 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions - GlobeNewsWire
- 4 weeks ago - Incyte Completes Acquisition of Escient Pharmaceuticals - Business Wire
- 6 weeks ago - Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings - Business Wire
- 6 weeks ago - Incyte to Present at Upcoming Investor Conference - Business Wire